Last reviewed · How we verify

NCT03360539: NFP

Nurse-Family Partnership Impact Evaluation in South Carolina

Active, enrolled NA Results posted Last updated 12 December 2025
What this trial tests

NA trial testing Nurse-Family Partnership in Preterm Birth in 5,670 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 April 2016
Primary endpoint
1 April 2023
1 April 2046

Quick facts

Lead sponsorHarvard School of Public Health (HSPH)
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment5,670
Start date1 April 2016
Primary completion1 April 2023
Estimated completion1 April 2046
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Harvard School of Public Health (HSPH)

Who can join

Adults 15 to 55, female only, with Preterm Birth or Injuries. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With a Composite Birth Outcome Primary · 0-7 days after index birth; vital records, mortality records, and fetal death records

Composite of at least one of: small for gestational (SGA), or low birth weight (LBW) less than 2500 grams, preterm birth (PTB) less than 37 weeks' gestation (obstetric estimate), or perinatal mortality (fetal death at or after 20 weeks of gestation or mortality in the first 7 days of life).

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership892
Control430
Number of Participants Whose Child Experienced a Major Injury or Concern for Abuse or Neglect Primary · within 24 months after index birth; Medicaid claims or hospital discharge data

Composite of at least one health care encounter or mortality associated with International Classification of Diseases (ICD) codes indicating either major injury, or, concern for abuse or neglect for the participant's index child(ren).

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership901
Control438
Number of Participants With an Inter-birth Interval of < 21 Months Primary · within 21 months after index birth; vital records

Having a subsequent birth within the first 21 months of the index birth

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership363
Control199
Number of Participants With an Infant Born Small for Gestational Age (SGA) Secondary · At index birth; vital records

Infant birth weight below the 10th percentile for infants of the same gestational age

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership553
Control265
Number of Participants With an Infant Born Large for Gestational Age (LGA) Secondary · At index birth birth; vital records

Infant birth weight above the 90th percentile for infants of the same gestational age

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership166
Control95
Number of Participants With an Infant Born With Low Birth Weight (LBW) Secondary · At index birth; vital records

Number of participants with an infant born with a birth weight of less than 2500 grams.

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership436
Control219
Number of Participants With an Infant With Very Low Birth Weight Secondary · At index birth; vital records

Number of participants with an infant born with a birth weight of less than 1500 grams.

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership78
Control48
Birth Weight (Continuous) Secondary · At index birth; vital records

A continuous measure of infant birth weight (grams)

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership3085.2± 609.6
Control3095.7± 38.1
Number of Participants With a Preterm Birth Secondary · At index birth; vital records

Infant born before 37 weeks' gestation (obstetric estimate)

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership379
Control190
Number of Participants With an Extremely Preterm Birth Secondary · At index birth; vital records

Number of participants with an infant born before 28 weeks' gestation.

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership32
Control16
Gestational Age at Birth Secondary · At index birth; vital records

Gestational age at birth in weeks (continuous)

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership38.2± 2.3
Control38.1± 2.3
Number of Participants Experiencing Perinatal Mortality Secondary · Within 1 week after index birth; mortality records and fetal death records

Fetal death at or after 20 weeks of gestation or mortality in the first 7 days of life

GroupValue95% CI
Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership27
Control10

Sponsor's own description

This study evaluates the effects of the Nurse Family Partnership (NFP), an established home-visiting program, using a scientifically rigorous individual-level randomized controlled trial. The study will be based in South Carolina, where a Medicaid waiver in combination with a pay-for-success contract will allow expansion of the program to women on Medicaid. The study plans to enroll 4000 low-income, first time mothers and their children into the intervention group, and another 2000 into the control group. The study will evaluate the program's impacts on outcomes using administrative records. This study aims to yield new evidence on the effect of NFP in a modern context, applied to a new population, across a broad range of outcomes, and financed by a novel public-private partnership based on accountability for outcomes.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Effect of an Intensive Nurse Home Visiting Program on Adverse Birth Outcomes in a Medicaid-Eligible Population: A Randomized Clinical Trial.
    McConnell MA, Rokicki S, Ayers S, Allouch F, et al · · 2022 · cited 33× · PMID 35788794 · DOI 10.1001/jama.2022.9703
  2. Protocol for a randomized controlled trial evaluating the impact of the Nurse-Family Partnership's home visiting program in South Carolina on maternal and child health outcomes.
    McConnell MA, Zhou RA, Martin MW, Gourevitch RA, et al · · 2020 · cited 7× · PMID 33276816 · DOI 10.1186/s13063-020-04916-9
  3. Intensive Nurse Home Visiting and Early Childhood Outcomes: A Randomized Clinical Trial.
    Swanson K, Ayers S, Oviedo D, Zhou RA, et al · · 2025 · cited 6× · PMID 40522648 · DOI 10.1001/jamapediatrics.2025.1600
  4. Home Visits and the Use of Routine and Emergency Postpartum Care Among Low-Income People: A Secondary Analysis of a Randomized Clinical Trial.
    Rokicki S, Oviedo D, Perreault N, Zera C, et al · · 2024 · cited 4× · PMID 39714843 · DOI 10.1001/jamanetworkopen.2024.51605
  5. Effect of an Intensive Nurse Home Visiting Program on Postpartum Contraceptive Use and Birth Spacing: A Randomized Controlled Trial.
    Steenland MW, Oviedo D, Bates MA, Zhou A, et al · · 2025 · cited 2× · PMID 39671266 · DOI 10.1097/aog.0000000000005786
  6. Impact of nurse home visiting on take-up of social safety net programs in a Medicaid population.
    Rokicki S, Oviedo D, Perreault N, Bates MA, et al · · 2025 · cited 1× · PMID 40177469 · DOI 10.1093/haschl/qxaf038

Verify or expand the search:

Other trials of Nurse-Family Partnership

Trials testing the same drug.

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

Other Harvard School of Public Health (HSPH) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03360539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing